E Point Perfect – Interesting and beneficial content
Law \ Legal

Court Rules Pfizer’s Copay Assistance Program Violates Anti-Kickback Law


The Court of Appeals for the Second Circuit ruled Monday that Pfizer’s program to make its drug tafamidis more affordable violated the federal Anti-Kickback Statute (“AKS”), 42 U.S.C. § 1320a-7(b)(2)(B).

The drug is currently the only drug approved by the United States to treat transthyretin amyloid cardiomyopathy, a rare and progressive heart condition, and costs about $225,000 per year. Because the condition primarily affects older Americans, most patients are covered by Medicare. However, patients are still responsible for a co-pay of about $13,000 per year. Pfizer’s proposed program would have directly covered a patient’s co-pay if they met certain criteria.

Pfizer initially consulted HHS for an advisory opinion. The Department determined that Pfizer’s proposal would violate the AKS, which prohibits “knowingly and willfully” offering or paying any “remuneration” to “induce” an individual to purchase a federally reimbursable healthcare product. Pfizer brought suit in the United States District Court for the Southern District of New York under the Administrative Procedure Act, challenging the agency’s interpretation of the AKS. The court granted summary judgment for the government, rejecting Pfizer’s argument which would require an element of “corrupt” intent to impose liability under the statute. The Court of Appeals for the 2nd Circuit affirmed the district court judgment.


Source link

Related posts

CorpFin Adds New Offices for Crypto Assets and Industrial Applications and Services

Disposition ‘not made for value’ under s 26(1) of Insolvency Act means for no value at all

DHS Extends I-9 Flexibility Due to COVID-19 … Yet Again

ESG: What is it, and Why Does it Matter to Mayer Brown?

People of Pacific: Associate Dean Larry Levine

Where is Professional Development Headed in Law? Find Out at This Virtual Conference